97180 ⎘
Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily against integrin beta1-subunit-containing molecules, e.g. CD29, CD49
METHODS, SYSTEMS, AND KITS FOR TREATMENT OF INFLAMMATORY DISEASES TARGETING TL1A
#2SINGLE-CHAIN NATALIZUMAB ANTIBODY-TRANSFERRIN FUSION PROTEIN FOR ENHANCED EFFICACY AND INDICATIONS
#3ANTIBODIES AGAINST INTEGRIN ALPHA 11 BETA 1
#4APPLICATION OF ITIH1 IN PREPARATION OF DRUG FOR TREATMENT OF HEPATOCELLULAR CARCINOMA
#5METHODS FOR TREATING ENDOMETRIAL AND OVARIAN HYPERPROLIFERATIVE DISORDERS
#6NANOBODY BASED IMAGING AND TARGETING OF ECM IN DISEASE AND DEVELOPMENT
#7TREATMENT OF A DISEASE OR CONDITION IN A TISSUE ORIGINATING FROM THE ENDODERM
#8PHARMACEUTICAL ASSOCIATION OF GROWTH FACTOR RECEPTOR AGONIST AND ADHESION PROTEIN INHIBITOR FOR CONVERTING A NEOPLASTIC CELL INTO A NON-NEOPLASTIC CELL AND USES THEREOF
#9METHODS FOR MODULATING AN IMMUNE RESPONSE TO CANCER OR TUMOR CELLS
#10INTEGRIN ALPHA-7 BETA-1 ANTIBODIES AND USES THEREOF
#11COMPOSITION FOR PREVENTING OR TREATING MYOCARDITIS, COMPRISING VLA-4 INHIBITOR
#12Treatment Methods for Fibrosis Targeting SMOC2
#13Integrin Alpha10 Antibody
#14DETERMINING WHETHER AN IBD PATIENT WILL RESPOND TO 5-ASA THERAPY
#15USE OF INTEGRIN a5b1 INHIBITORS IN THE TREATMENT OF PULMONARY HYPERTENSION AND HEART FAILURE
#16METHODS AND COMPOSITIONS FOR ALTERING A TUMOR MICROBIOME
#17METHOD OF ASSESSING RISK OF PML
#18METHODS OF TREATING INFLAMMATORY AND AUTOIMMUNE DISEASES
#19ANTI-ALPHA V BETA 8 INTEGRIN ANTIBODIES AND METHODS OF USE
#20COMPOSITIONS COMPRISING A T CELL REDIRECTION THERAPEUTIC AND A VLA-4 ADHESION PATHWAY INHIBITOR
#21ANTIBODIES AGAINST INTEGRIN ALPHA 11 BETA 1
#22COMPOSITIONS AND METHODS OF TREATING SARCOMA LUNG METASTASIS
#23METHODS OF ASSESSING THE RISK OF DEVELOPING PROGRESSIVE MULTIFOCAL LEUKOENCEPHALOPATHY IN PATIENTS TREATED WITH VLA-4 ANTAGONISTS
#24Targeting Extracellular Matrix Proteins to Regulate NK Cell Function in Peripheral Tissues
#25ALPHA 5 BETA 1 INTEGRIN BINDING AGENTS AND USES THEREOF
#26COMPOSITIONS COMPRISING A T CELL REDIRECTION THERAPEUTIC AND AN ANTI-CD44 THERAPEUTIC
#27COMPOSITIONS AND METHODS FOR TREATING CHRONIC ACTIVE WHITE MATTER LESIONS / RADIOLOGICALLY ISOLATED SYNDROME
#28ANTIBODIES AGAINST INTEGRIN HETERODIMERS AND USES THEREOF
#29METHODS OF INHIBITING INTEGRIN ALPHA9BETA1 ACTIVITY
#30STABLE AQUEOUS BUFFER FREE FORMULATION OF AN INTEGRIN ANTIBODY
#31ANTI-VLA-4 ANTIBODIES
#32B Cell and Antibody Assays in Autoimmune Diseases and Treatment Thereof
#33PROTEIN, POLYNUCLEOTIDE, VECTOR, HOST CELL, COMPOSITION, METHOD FOR TREATING AN ILLNESS, IN-VITRO METHOD FOR PREDICTING MULTIPLE SCLEROSIS, AND USE OF A PROTEIN OR COMPOSITION
#34BIPHASIC SUBCUTANEOUS DOSING REGIMENS FOR ANTI-VLA-4 ANTIBODIES
#35BINDING PROTEINS COMPRISING THE EXTRACELLULAR DOMAIN OF CD39 AND METHODS OF TREATING OR PREVENTING NEUROLOGICAL DISEASES
#36METHODS FOR TREATING INFLAMMATORY BOWEL DISEASES WITH a4B7 INTEGRIN ANTAGONISTS
#37COMBINATION THERAPY FOR ALPORT RENAL DISEASE
#38NANOBODY BASED IMAGING AND TARGETING OF ECM IN DISEASE AND DEVELOPMENT
#39TARGETING ALPHA3BETA1 INTEGRIN FOR TREATMENT OF CANCER AND OTHER DISEASES
#40CAR T CELLS TARGETING THE INTEGRIN ALPHAV BETA3 EXHIBIT ROBUST ANTI-TUMOR RESPONSES AGAINST GLIOMAS AND OTHER SOLID TUMOR MALIGNANCIES
#41METHODS OF TREATING INFLAMMATORY AND AUTOIMMUNE DISEASES WITH NATALIZUMAB
#42MULTISPECIFIC ANTIGEN-BINDING MOLECULE WITH IMPROVED INTERNALIZATION CHARACTERISTICS
#43COMPOSITIONS AND METHODS FOR GAMMA DELTA TCR REPROGRAMMING USING FUSION PROTEINS
#44ANTIBODIES AGAINST INTEGRIN ALPHA 11 BETA 1
#45TREATMENT OF NEUROINFLAMMATORY DISEASE
#46Method of formulating a pharmaceutical composition comprising administering an immune modulator to the small intestine
#47Method of assessing risk of PML
#48SYNTHETIC COMPOUND
#49TREATING CHRONIC LIVER DISEASE
#50METHODS FOR REDUCING TOXICITY OF A CHEMOTHERAPEUTIC DRUG
#51ANTI-INTEGRIN ANTIBODIES AND USES THEREOF
#52METHODS FOR DIAGNOSING AND TREATING INFLAMMATORY BOWEL DISEASE
#53ADMINISTRATION OF AGENTS FOR THE TREATMENT OF INFLAMMATION
#54Treatment methods for fibrosis targeting SMOC2
#55USE OF INTEGRIN INHIBITORS FOR TREATMENT OR PREVENTION OF A NEUROLOGICAL IMMUNITY DISORDER AND/OR NERVOUS SYSTEM INJURY
#56AQUEOUS PHARMACEUTICAL FORMULATIONS
#57Methods and Compositions for Improving Antiangiogenic Therapy with Anti-Integrins
#58ANTI-INTEGRIN BETA-1 ANTIBODY COMPOSITIONS AND METHODS OF USE THEREOF
#59COMPOSITIONS AND METHODS FOR TREATING NECROTIZING ENTEROCOLITIS
#60Anti-VLA-4 antibodies
#61Compositions and methods of treating sarcoma lung metastasis
#62PHARMACEUTICAL COMPOSITIONS AND DOSAGE REGIMENS CONTAINING ANTI-ALPHA(V)BETA(6) ANTIBODIES
#63COMPOSITIONS COMPRISING A T CELL REDIRECTION THERAPEUTIC AND A VLA-4 ADHESION PATHWAY INHIBITOR
#64MANGANESE SUPPLEMENTATION FOR CONTROL OF GLYCOSYLATION IN MAMMALIAN CELL CULTURE PROCESS
#65COMPOSITIONS AND METHODS FOR TREATING INFLAMMATORY BOWEL DISEASE USING A COMBINATION THERAPY OF SMALL MOLECULE INHIBITORS OF C-C CHEMOKINE RECEPTOR TYPE 9 (CCR9) AND ANTI-ALPHA4BETA7 INTEGRIN BLOCKING ANTIBODIES
#66AQUEOUS PHARMACEUTICAL FORMULATIONS
#67TARGETED THERAPY FOR SMALL CELL LUNG CANCER
#68Method of treating Crohn's disease by administering a triple combination therapy of anti-integrin antibody, adalimumab and methotrexate
#69Anti-VLA-4 antibodies having reduced effector function
#70Mono and bispecific antibody binding to hERG1 and hERG1/integrin beta 1
#71Methods of inhibiting integrin α9β1 activity
#72ANTIBODY AGAINST ALPHA-11 INTEGRIN AND ITS USE
#73Pharmaceutical Composition For Preventing Or Treating Tissue Adhesion Comprising Integrin a2ß1 Inhibitors
#74COMPOSITIONS AND METHODS FOR TREATING SEXUAL DYSFUNCTION
#75METHODS OF TREATING STROKE
#76Method of assessing risk of PML
#77Methods for diagnosing and treating inflammatory bowel disease
#78Bispecific antibody constructs and methods of use
#79Compositions and methods for treating inflammatory bowel disease using a combination therapy of small molecule inhibitors of C-C chemokine receptor type 9 (CCR9) and anti-α4β7 integrin blocking antibodies
#80COMPOSITIONS AND METHODS FOR TREATMENT OF STROKE AND OTHER CNS DISORDERS
#81Methods for treatment or prevention of a neurological immunity disorder
#82Methods of treating inflammatory and autoimmune diseases with natalizumab
#83Administration of agents for the treatment of inflammation
#84Compositions and methods for treating inflammatory bowel disease using a combination therapy of small molecule inhibitors of C—C chemokine receptor type 9 (CCR9) and anti-α4β7 integrin blocking antibodies
#85Glucose oxidase-nanoparticle bioconjugates for cancer treatment
#86S1P modulating agents
#87MIRNA BASED TREATMENT MONITORING IN MULTIPLE SCLEROSIS
#88Hetero-Dimeric Immunoglobulins
#89Disintegrin variants and pharmaceutical uses thereof
#90AQUEOUS PHARMACEUTICAL FORMULATIONS
#91Anti-VLA-4 antibodies
#92MULTISPECIFIC ANTIGEN-BINDING MOLECULE WITH IMPROVED INTERNALIZATION CHARACTERISTICS
#93ANTIBODY FORMULATIONS
#94PHARMACEUTICAL ASSOCIATION OF GROWTH FACTOR RECEPTOR AGONIST AND ADHESION PROTEIN INHIBITOR FOR CONVERTING A NEOPLASTIC CELL INTO A NON-NEOPLASTIC CELL AND USES THEREOF
#95Methods of treating inflammatory and autoimmune diseases with natalizumab
#96Compositions and methods to treat solid tumors
#97ANTI-ITGA3 ANTIBODIES, ACTIVATABLE ANTI-ITGA3 ANTIBODIES, AND METHODS OF USE THEREOF
#98Treatment methods for fibrosis targeting SMOC2
#99Methods for diagnosing and treating inflammatory bowel disease
#100RECOMBINANT PRODUCTION OF MONOCLONAL ANTIBODIES
#101Nanobody based imaging and targeting of ECM in disease and development
#102Methods for Treating Disorders Associated with Fibrosis and Systemic Sclerosis
#103Synthetic compound
#104ANTI-VLA1 (CD49A) ANTIBODY PHARMACEUTICAL COMPOSITIONS
#105Triple combination therapy for treating Crohn's disease
#106Method of assessing risk of PML
#107METHODS OF TREATING STROKE
#108Methods for reducing toxicity of a chemotherapeutic drug
#109Methods And Compositions For Treating And Preventing Disease Associated With Alpha 8 Beta 1 Integrin
#110Compositions and methods of treating sarcoma lung metastasis
#111SIP modulating agents
#112Angiopoietin-Like 4 and Its Use in Modulating Cell Leakiness
#113Anti-integrin β1 antibody compositions and methods of use thereof
#114IMMUNOAFFINITY PURIFICATION OF ANTIBODIES USING MIMETOPES
#115Methods and compositions for improving antiangiogenic therapy with anti-integrins
#116Anti-VLA-4 antibodies
#117JAM-C antibodies and methods for treatment of cancer
#118Manganese supplementation for control of glycosylation in mammalian cell culture process
#119Hetero-Dimeric Immunoglobulins
#120Lung cancer diagnosis marker, antibody and application thereof
#121S1P modulating agents
#122REGENERATION OF AGED SATELLITE CELLS
#123TREATMENT OF OCULAR DISORDERS
#124Antibodies to VLA-1
#125Methods for treating and/or limiting development of diabetes
#126ADMINISTRATION OF AGENTS FOR THE TREATMENT OF INFLAMMATION
#127JAM-C antibodies and methods for treatment of cancer
#128Methods of treating inflammatory and autoimmune diseases with natalizumab
#129T-cell redirecting bispecific antibodies for treatment of disease
#130Enhancing the therapeutic activity of immune checkpoint inhibitor
#131Methods for diagnosing and treating inflammatory bowel disease
#132COMPOSITIONS AND METHODS FOR PRODUCING GLYCOPROTEINS
#133Compositions and methods to treat solid tumors
#134T-cell redirecting bispecific antibodies for treatment of disease
#135Methods and compositions for modulating lymphangiogenesis, E.G., to treat transplant rejection, in a subject
#136Anti-ITGA3 antibodies, activatable anti-ITGA3 antibodies, and methods of use thereof
#137SELECTION AND TREATMENT OF SUBJECTS
#138Use of antagonists of the interaction between HIV GP120 and α4β7 integrin
#139Targeted therapy for small cell lung cancer
#140Monoclonal antibody capable of binding integrin alpha 10 beta 1
#141S1P modulating agents
#142INTEGRIN-MODULATING THERAPIES FOR TREATING FIBROTIC DISEASE
#143Methods for treating and/or limiting development of diabetes
#144T-cell redirecting bispecific antibodies for treatment of disease
#145PEPTIDE OR PEPTIDE COMPLEX BINDING TO ALPHA2 INTEGRIN AND METHODS AND USES INVOLVING THE SAME
#146COMPOSITIONS AND METHODS FOR TREATMENT OF STROKE
#147Method of assessing risk of PML
#148Compositions and methods for treating inflammatory bowel disease using a combination therapy of small molecule inhibitors of C-C chemokine receptor 9 (CCR9) and anti-α4β7 integrin blocking antibodies
#149Use of antagonists of the interaction between HIV GP120 and α4β7 integrin
#150immunogens and related materials and methods
#151Anti-alpha V beta 6 antibodies and uses thereof
#152Anti-VLA1 (CD49A) antibody pharmaceutical compositions
#153Treatment of ocular disorders
#154INHIBITOR OF INTEGRIN FOR THE TREATMENT OR PREVENTION OF TUMOURS
#155Antibodies to VLA-1
#156COMPOSITIONS AND METHODS FOR PRODUCING GLYCOPROTEINS
#157Methods for treating and/or limiting development of diabetes
#158JAM-C antibodies and methods for treatment of cancer
#159Fc variant antibodies and their uses
#160NOVEL ANTI- ALPHA5 BETA1 ANTIBODIES AND USES THEREOF
#161EXTENDED TREATMENT OF MULTIPLE SCLEROSIS
#162ADMINISTRATION OF AGENTS FOR THE TREATMENT OF INFLAMMATION
#163Use of integrin beta subunits in the diagnosis of venous thromboembolism
#164Fibrosis suppression by inhibiting integrin α-8 β-1 function
#165THERAPEUTIC USES OF HUMANIZED ANTIBODIES AGAINST ALPHA-4 INTEGRIN
#166STEROID SPARING AGENTS AND METHODS OF USING SAME
#167MiRNA based treatment monitoring in multiple sclerosis
#168ANTI-ALPHA2 INTEGRIN ANTIBODIES AND THEIR USES
#169Anti-integrin β1 antibody compositions and methods of use thereof
#170COMPOUNDS AND METHODS FOR THE MODULATION OF BETA-1 INTEGRIN FUNCTION TO MEDIATE TISSUE REPAIR
#171Administration of alpha4beta7 hetero-dimer-specific antibody
#172THERAPIES FOR CHRONIC RENAL FAILURE USING ONE OR MORE INTEGRIN ANTAGONISTS
#173Hetero-dimeric immunoglobulins
#174ALPHA5-BETA1 ANTIBODIES AND THEIR USES
#175Method for the treatment of inflammatory disorders
#176Monoclonal antibody capable of binding integrin alpha 10 beta 1
#177Hetero-dimeric immunoglobulins
#178Methods and compositions for modulating lymphangiogenesis, e.g., to treat transplant rejection, in a subject
#179T-cell redirecting bispecific antibodies for treatment of disease
#180Cell display of antibody libraries
#181Anti-leukocyte recruitment therapy for the treatment of seizures and epilepsy
#182Antibody formulations
#183Bladder cancer tumor marker, antibody and use thereof
#184Anti-α5β1 antibodies and uses thereof
#185Therapeutic Uses of Humanized Antibodies Against ALPHA-4 Integrin
#186Anti-alpha2 integrin antibodies and their uses
#187METHODS OF TREATING CENTRAL NERVOUS SYSTEM ISCHEMIC OR HEMORRHAGIC INJURY USING ANTI ALPHA4 INTEGRIN ANTAGONISTS
#188Methods for treating and/or limiting development of diabetes
#189Integrin alpha-2 binding agents and use thereof to inhibit cancer cell proliferation
#190EXTENDED TREATMENT OF MULTIPLE SCLEROSIS
#191VLA-4 AS A BIOMARKER FOR PROGNOSIS AND TARGET FOR THERAPY IN DUCHENNE MUSCULAR DYSTROPHY
#192Integrin alpha 8-beta 1-specific monoclonal antibody
#193METHOD FOR INHIBITING "MELANOMA INHIBITORY ACTIVITY" MIA
#194Anti-alpha5/beta1 antibody
#195Methods of treating inflammatory and autoimmune diseases with natalizumab
#196ANTIBODIES TO VLA-1
#197Antibodies
#198Antibodies
#199Methods for detecting and inhibiting angiogenesis
#200TARGETED BINDING AGENTS DIRECTED TO a5BETA1 AND USES THEREOF
#201Method for the treatment of inflammatory disorders
#202Insulin-like growth factor signaling and integrin
#203Monoclonal antibody capable of binding integrin alpha 10 beta 1
#204Recombinant anti-VLA4 antibody molecules
#205Alpha5-beta1 antibodies and their uses
#206Perlecan domain V protects, repairs and restores ischemic brain stroke injury and motor function
#207PHARMACEUTICAL COMPOSITION AND METHOD FOR IDENTIFYING A CANCEROUS AND/OR AN INFLAMMATORY DISEASE IN A PATIENT
#208THERAPIES FOR CHRONIC RENAL FAILURE USING ONE OR MORE INTEGRIN ANTAGONISTS
#209Chimeric and humanized antibodies to α5β1 integrin that modulate angiogenesis
#210AMINO ACID SEQUENCES DIRECTED AGAINST INTEGRINS AND USES THEREOF
#211Antibodies to VLA-1
#212Set of Antiangiogenic Molecules and Use Thereof
#213METHODS FOR DETECTING AND INHIBITING ANGIOGENESIS
#214Methods of modulating angiogenesis via TRPV4
#215Frozen compositions and methods for piercing a substrate
#216Anti-alpha2 integrin antibodies and their uses
#217Cytomegalovirus disintegrin-like peptides
#218COMBINATION TREATMENT FOR OCULAR DISEASES
#219Use of antagonists of the interaction between HIV GP120 and A4B7 integrin
#220Alpha 5 beta 1 and its ability to regulate the cell survival pathway
#221Enriched pancreatic stem cell and progenitor cell populations, and methods for identifying, isolating and enriching for such populations
#222ADMINISTRATION OF AGENTS FOR THE TREATMENT OF INFLAMMATION
#223TREATMENT OF IDIOPATHIC THROMBOCYTOPENIC PURPURA
#224Mutant antibody Fc domains and fusion proteins thereof
#225Alpha 5-beta 1 antibodies and their uses
#226Anti-ADAM-15 antibodies and utilization of the same
#227Use of Anti-Alpha5Beta1 Antibodies to Inhibit Cancer Cell Proliferation
#228Method for inhibiting “melanoma inhibitory activity” MIA
#229Antibodies to VLA-1
#230Compositions and Methods to Treat Acute Myelogenous Leukemia
#231Anti- α5 β1 antibodies and uses thereof
#232Methods for Detecting and Inhibiting Angiogenesis
#233Engineered anti-alpha V-integrin hybrid antibodies
#234Methods of treating stroke and traumatic brain injury using humanized AQC2 anti-VLA-1 antibodies
#235Recombinant anti-VLA4 antibody molecules
#236METHOD FOR REDUCING ALLERGEN-INDUCED AIRWAY HYPERRESPONSIVENESS
#237Methods of treating inflammatory and autoimmune diseases with natalizumab
#238Methods of treating multiple myeloma and myeloma-induced bone resorption using integrin antagonists
#239Treatment with anti-alpha2 integrin antibodies
#240Frozen compositions and methods for piercing a substrate
#241Use of vascular endothelial growth factor receptor 1+ cells in treating and monitoring cancer and in screening for chemotherapeutics
#242NOVEL RECEPTOR FOR CD40L AND USES THEREOF
#243Frozen compositions and methods for piercing a substrate
#244Frozen compositions and methods for piercing a substrate
#245Frozen compositions and array devices thereof
#246Frozen compositions and methods for piercing a substrate
#247Compositions and methods for biological remodeling with frozen particle compositions
#248Frozen piercing implements and methods for piercing a substrate
#249Frozen compositions and methods for piercing a substrate
#250Anti-leukocyte recruitment therapy for the treatment of seizures and epilepsy
#251Methods of humanizing immunoglobulin variable regions through rational modification of complementarity determining residues
#252Compounds and methods for the modulation of beta-1 integrin function to mediate tissue repair
#253Methods of inhibiting alpha-4-dependent interactions with VCAM-1 with anti-VLA-4 antibodies
#254Methods for inhibition of lymphangiogenesis and tumor metastasis
#255Method of increasing radiation sensitivity by inhibition of beta one integrin
#256Enriched Pancreatic Stem Cell and Progenitor Cell, Populations, and Methods For Identifying, Isolating and Enriching For Such Populations
#257Method for the treatment of inflammatory disorders
#258Chimeric and humanized antibodies to α5β1 integrin that modulate angiogenesis
#259Methods of inhibiting amyloid toxicity
#260COMBINATORIAL THERAPY
#261TREATMENT FOR MULTIPLE SCLEROSIS
#262Monoclonal antibody capable of binding integrin alpha 10 beta 1
#263DELAYING OR PREVENTING ONSET OF MULTIPLE SCLEROSIS
#264Method for altering hematopoietic progenitor cell adhesion, differentiation, and migration
#265Anti-HPA
#266Antibodies
#267CYR61 COMPOSITIONS AND METHODS
#268High affinity human and humanized anti-alpha5beta1 integrin function blocking antibodies with reduced immunogenicity
#269USE OF ANTI-INTEGRIN ANTIBODIES FOR REDUCING SCAR TISSUE FORMATION
#270PHARMACEUTICAL COMBINATIONS
#271Antibodies to VLA-1
#272Extended Treatment of Multiple Sclerosis
#273Methods for Discovering Antibodies Specific to Cancer Cells and Antibodies Discovered Thereby
#274Anti-angiogenic targets for cancer therapy
#275Chimeric and humanized antibodies to α5β1 integrin that modulate angiogenesis
#276Treatment of Severe Multiple Sclerosis
#277METHODS FOR DETECTING AND INHIBITING ANGIOGENESIS USING ANTAGONISTS
#278Methods of treating cognitive impairment
#279METHODS FOR DETECTING AND INHIBITING ANGIOGENESIS
#280Tissue repair by modulation of beta-1 integrin biological function
#281METHODS FOR DETECTING AND INHIBITING ANGIOGENESIS USING PEPTIDES
#282Methods of implanting mesenchymal stem cells for tissue repair and formation
#283ANTI-OSTEOPONTIN ANTIBODY AND USE THEREOF
#284Methods of treating inflammatory and autoimmune diseases with alpha-4 inhibitory compounds
#285Composition and Method for Elevating Gene Transfer Efficiency
#286Method for the discrimination and isolation of mammary epithelial stem and colony-forming cells
#287Chimeric and humanized antibodies to α5β1 integrin that modulate angiogenesis
#288Chimeric and humanized antibodies to α5β1 integrin that modulate angiogenesis
#289Anti-leukocyte recruitment therapy for the treatment of seizures and epilepsy
#290Methods and compositions for prevention or treatment of inflammatory-related diseases and disorders
#291Compositions for inhibiting Sema7A and VLA-1 interaction and the methods of using the same
#292Treatment for inflammatory bowel disease
#293Treatment for asthma with α4-specific antibodies
#294Agent for inhibiting proliferation of neural stem cells
#295Method of increasing radiation sensitivity by inhibition of beta one integrin
#296Methods of treating inflammatory and autoimmune diseases with natalizumab
#297Enriched Pancreatic Stem Cell and Progenitor Cell Populations, and Methods for Identifying, Isolating and Enriching for Such Populations
#298Methods of treating inflammatory and autoimmune diseases with natalizumab
#299Altered antibodies having improved antigen-binding affinity
#300Anti-α2 integrin antibodies and their uses